When putting together your watch list, focus on stocks with an 80 or higher RS Rating. Incyte is one stock that just reached the mark, now earning a score of 81.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the best-performing stocks often have an RS Rating north of 80 as they begin their biggest climbs.
Risk Management In The Stock Market: How Much Money To Invest Now
Incyte is working on a consolidation with an 83.95 entry. See if the stock can break out in volume at least 40% above average.
Earnings growth fell in the most recent quarter from 0% to -3%. But revenue gains moved higher, from 9% to 24%.
Incyte earns the No. 59 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!